Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 15/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4939386 | 1.00 | KDM1A (0.53) | KDM1AMAOATACR1MAOBCYP2D6 | |
| Bromide SCHEMBL4939395 | 1.00 | KDM1A (0.53) | KDM1AMAOATACR1MAOBCYP2D6 | |
| SCHEMBL4939404 | 0.98 | KDM1A (0.54) | KDM1AMAOATACR1MAOBCYP2D6 | |
| SCHEMBL4939427 | 0.98 | KDM1A (0.54) | KDM1AMAOATACR1MAOBCYP2D6 | |
| SCHEMBL4939399 | 0.98 | KDM1A (0.54) | KDM1AMAOATACR1MAOBCYP2D6 | |
| SCHEMBL4939411 | 0.98 | KDM1A (0.54) | KDM1AMAOATACR1MAOBCYP2D6 | |
| SCHEMBL4939417 | 0.98 | KDM1A (0.54) | KDM1AMAOATACR1MAOBCYP2D6 | |
| SCHEMBL9294678 | 0.89 | TACR1 (0.64) | TACR1CYP2D6 | |
| SCHEMBL5555958 | 0.89 | TACR1 (0.64) | TACR1CYP2D6 | |
| SCHEMBL9294139 | 0.89 | TACR1 (0.64) | TACR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | HUMPHREY JOHN MICHAEL | 2008-09-11 | — | — | US | disclosed |
| US-7381741-B2 | In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors | PFIZER INC (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1753718-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005115976-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PBK, KCND3, KCND2 | KDM1A 1363/4885MAOA 3154/4885TACR1 33/4885 |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PBK, KCND3, KCND2 | KDM1A 1363/4885MAOA 3154/4885TACR1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.